MaxCyte Inc. (MXCT): Stephens sees an early phase of investments in expanding market reach with 186% price potential
Reading Time: 2 minutes
MaxCyte Inc. (MXCT) is a cell engineering company specializing in groundbreaking platform technologies to advance next-generation cell therapies. With over 20 years of experience in this field, MaxCyte has established its ExPERT platform, which is based on flow electroporation technology. This platform is designed to comprehensively support the rapidly growing cell therapy market – from discovery and development to the commercialization of cell-based drugs. In addition to cell therapies, the technology is also used in the development of small...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
